Skip to main content

BI 690817 + Empagliflozin: Aldosterone synthase inhibitor + SGLT2 inhibitor

Phase 2
Indication: Chronic kidney disease

US FDA Fast Track Designation

This compound is under investigation, further information will be available soon.

Partner enquiries
Join our team

Additional Links

Related Press Releases

Read more

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Read more